Helius Medical Technologies, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
NASDAQ
Solana Company reports a $99.8 million net loss for Q1 2026 driven by digital asset volatility and announces a major executive leadership transition.
NASDAQ
Solana Company transformed into a Solana token treasury vehicle, raised over $500M via PIPE/ATM, amassed $350M of SOL by 9/30, but recorded a $352.8M Q3 net loss driven by derivative warrant liabilities and financing costs.
NASDAQ
Helius Medical Technologies reported a significantly wider net loss in Q2 2025 due to decreased product sales, despite successful capital raises and regaining Nasdaq compliance.
NASDAQ
Helius Medical Technologies reports a net loss for Q1 2025, faces Nasdaq compliance issues, and continues to pursue strategic alternatives.
NASDAQ
Helius Medical Technologies reported a net loss of $3.7 million for the third quarter of 2024, facing challenges with reimbursement pricing and manufacturing transitions.
NASDAQ
Helius Medical Technologies reported a net loss of $1.6 million for the second quarter of 2024, while making progress on commercialization and reimbursement efforts for its PoNS device.
NASDAQ
Helius Medical Technologies reported a net loss of $2.5 million for the first quarter of 2024, while also securing $5.6 million in net proceeds from a public offering in May.